Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMDANASDAQ:GNFTNASDAQ:INMBNASDAQ:LOGCNASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMDAGamida Cell$0.17$0.03▼$2.51$5.04M0.939.20 million shs23.04 million shsGNFTGENFIT$3.78+1.6%$4.12$2.55▼$6.42$186.24M1.0810,517 shs786 shsINMBINmune Bio$2.09-9.5%$7.21$1.91▼$11.64$53.09M1.34736,887 shs8.75 million shsLOGCLogicBio Therapeutics$6.81+2.4%$2.06$0.26▼$3.77$178.97M2.06168,718 shs197,757 shsTARAProtara Therapeutics$2.80-7.6%$3.26$1.60▼$10.48$116.90M1.35795,707 shs531,406 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMDAGamida Cell0.00%0.00%0.00%0.00%0.00%GNFTGENFIT+3.19%-2.23%-14.95%+8.41%+3.19%INMBINmune Bio-56.66%-62.86%-69.03%-69.57%-73.81%LOGCLogicBio Therapeutics0.00%-10.01%-18.90%-4.73%+16.46%TARAProtara Therapeutics+5.21%+5.21%-1.62%-24.44%+45.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMDAGamida CellN/AN/AN/AN/AN/AN/AN/AN/AGNFTGENFIT2.2501 of 5 stars3.54.00.00.02.70.00.0INMBINmune Bio2.0354 of 5 stars3.60.00.00.02.81.70.6LOGCLogicBio Therapeutics1.4346 of 5 stars0.04.00.04.70.60.80.6TARAProtara Therapeutics2.1477 of 5 stars3.61.00.00.03.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMDAGamida Cell 0.00N/AN/AN/AGNFTGENFIT 3.00Buy$13.00243.92% UpsideINMBINmune Bio 2.71Moderate Buy$22.80990.91% UpsideLOGCLogicBio Therapeutics 0.00N/AN/AN/ATARAProtara Therapeutics 3.14Buy$20.50632.14% UpsideCurrent Analyst Ratings BreakdownLatest LOGC, GNFT, GMDA, TARA, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025INMBINmune BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/1/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Underperform5/22/2025TARAProtara TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$21.004/28/2025TARAProtara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/16/2025TARAProtara TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$12.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMDAGamida Cell$1.78M0.00N/AN/A($0.02) per share0.00GNFTGENFIT$76.77M2.46$0.07 per share53.26$1.50 per share2.52INMBINmune Bio$10K4,802.82N/AN/A$1.45 per share1.44LOGCLogicBio Therapeutics$287M0.62N/AN/A$8.96 per share0.76TARAProtara TherapeuticsN/AN/AN/AN/A$4.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMDAGamida Cell-$63M-$0.63N/AN/AN/AN/AN/A-57.59%N/AGNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)INMBINmune Bio-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)LOGCLogicBio Therapeutics-$317M-$5.79N/A∞N/A-141.03%-81.98%-52.13%N/ATARAProtara Therapeutics-$44.60M-$1.72N/AN/AN/AN/A-36.37%-33.29%8/5/2025 (Estimated)Latest LOGC, GNFT, GMDA, TARA, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025LOGCLogicBio TherapeuticsN/A-$0.27N/A-$0.27N/AN/A5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 million5/8/2025Q1 2025TARAProtara Therapeutics-$0.47-$0.29+$0.18-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMDAGamida CellN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMDAGamida Cell213.142.162.09GNFTGENFIT0.081.231.23INMBINmune BioN/A2.642.64LOGCLogicBio TherapeuticsN/A31.6031.60TARAProtara TherapeuticsN/A18.0318.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMDAGamida Cell50.34%GNFTGENFIT2.24%INMBINmune Bio12.72%LOGCLogicBio Therapeutics46.05%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipGMDAGamida Cell3.40%GNFTGENFIT4.20%INMBINmune Bio35.70%LOGCLogicBio Therapeutics8.10%TARAProtara Therapeutics12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableINMBINmune Bio1022.98 million14.78 millionOptionableLOGCLogicBio Therapeutics6226.28 million24.16 millionOptionableTARAProtara Therapeutics3038.58 million33.76 millionOptionableLOGC, GNFT, GMDA, TARA, and INMB HeadlinesRecent News About These CompaniesProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 1 at 4:12 PM | globenewswire.comProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial CommunityJune 30 at 8:14 AM | quiverquant.comQProtara Therapeutics Announces Addition to the Russell 3000® IndexJune 30 at 8:00 AM | globenewswire.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of "Buy" from AnalystsJune 30 at 2:16 AM | americanbankingnews.comProtara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of "Buy" by BrokeragesJune 30 at 2:13 AM | marketbeat.comProtara Therapeutics, Inc. (TARA) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of DirectorsJune 23, 2025 | quiverquant.comQProtara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025June 14, 2025 | seekingalpha.comTwo Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA)June 14, 2025 | marketbeat.comAnalysts Set Expectations for TARA FY2026 EarningsJune 10, 2025 | marketbeat.comChutes & Ladders—Protara gears up for next steps with commercial proJune 7, 2025 | fiercebiotech.comFProtara Therapeutics, Inc. (NASDAQ:TARA) Position Increased by Bank of America Corp DEJune 7, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Buy" by AnalystsJune 5, 2025 | marketbeat.comThe Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and moreJune 4, 2025 | mmm-online.comMProtara Therapeutics names new Chief Commercial OfficerJune 4, 2025 | investing.comMillennium Management LLC Purchases 357,051 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)June 3, 2025 | marketbeat.comProtara Therapeutics Announces Appointment of William Conkling as Chief Commercial OfficerJune 2, 2025 | globenewswire.comJones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy RecommendationMay 23, 2025 | msn.comRichard Levy Spends US$64k On Protara Therapeutics StockMay 22, 2025 | finance.yahoo.comWith 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backingMay 16, 2025 | finance.yahoo.comProtara Therapeutics to Participate in Upcoming Investor ConferencesMay 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLOGC, GNFT, GMDA, TARA, and INMB Company DescriptionsGamida Cell NASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.GENFIT NASDAQ:GNFT$3.78 +0.06 (+1.61%) Closing price 03:56 PM EasternExtended Trading$3.75 -0.03 (-0.77%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.INmune Bio NASDAQ:INMB$2.09 -0.22 (-9.52%) Closing price 04:00 PM EasternExtended Trading$2.08 -0.01 (-0.53%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.LogicBio Therapeutics NASDAQ:LOGCLogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Protara Therapeutics NASDAQ:TARA$2.80 -0.23 (-7.59%) Closing price 04:00 PM EasternExtended Trading$2.78 -0.02 (-0.68%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
